Skip to main content
Erschienen in: Supportive Care in Cancer 9/2017

24.03.2017 | Original Article

Impact of dyspnea on advanced cancer patients referred to a palliative radiotherapy clinic

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Dyspnea is a debilitating symptom commonly experienced by advanced cancer patients that can lead to negative effects on function and quality of life (QOL). The present study aims to determine the relationship between dyspnea and other Edmonton Symptom Assessment System (ESAS) symptoms in palliative cancer patients referred to a radiotherapy clinic.

Methods

The presence and severity of dyspnea was measured using the ESAS. All patients that visited a palliative radiotherapy clinic between 1999 to 2002 and 2006 to 2009 and completed the ESAS were included. ESAS scores and other demographic and clinical information were extracted from a prospectively collected database. Statistical tests including chi-squared tests, Spearman correlations, and multivariate analysis were conducted to explore the relationship between dyspnea, other ESAS items, and other demographic factors. Kaplan-Meier overall survival curves were generated based on dyspnea severity.

Results

One thousand three hundred forty-four patients were included in the dyspnea analysis; reported moderate or severe dyspnea. Dyspnea severity was significantly associated with eight other ESAS interference severities (p < 0.001). Upon multivariate analysis, greater severity of dyspnea was significantly related to higher ESAS scores for tiredness, nausea, depression, anxious, drowsiness, and poor appetite (p < 0.05). The actuarial median survival time was 6.57 months (95% CI 5.91–7.29 months). There were highly significant differences in overall survival between those with none, mild, and moderate dyspnea (p < 0.0001).

Conclusion

Cancer patients often experience dyspnea along with a multitude of other symptoms. Moderate and severe dyspnea should be assessed and optimally managed to reduce functional and QOL debilitations. As presence of increased dyspnea severity is associated with worse overall survival, interventions should occur at the end of life to reduce symptom burden in palliative patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y (2002) Factors correlated with dyspnea in advanced lung cancer patients: organic causes and what else? J Pain Symptom Manag 23(6):490–500. doi:10.1016/S0885-3924(02)00400-1 CrossRef Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y (2002) Factors correlated with dyspnea in advanced lung cancer patients: organic causes and what else? J Pain Symptom Manag 23(6):490–500. doi:10.​1016/​S0885-3924(02)00400-1 CrossRef
4.
Zurück zum Zitat Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y (2002) Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manag 23(5):417–423. doi:10.1016/S0885-3924(02)00376-7 CrossRef Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y (2002) Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manag 23(5):417–423. doi:10.​1016/​S0885-3924(02)00376-7 CrossRef
6.
11.
Zurück zum Zitat Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CCD (2013) Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton symptom assessment scale in cancer patients: a systematic review. J Pain Symptom Manag 45(6):1083–1093. doi:10.1016/j.jpainsymman.2012.06.007 Oldenmenger WH, de Raaf PJ, de Klerk C, van der Rijt CCD (2013) Cut points on 0-10 numeric rating scales for symptoms included in the Edmonton symptom assessment scale in cancer patients: a systematic review. J Pain Symptom Manag 45(6):1083–1093. doi:10.​1016/​j.​jpainsymman.​2012.​06.​007
12.
Zurück zum Zitat Kamal AH, Maguire JM, Wheeler JL, Currow DC, Abernethy AP (2012) Dyspnea review for the palliative care professional: treatment goals and therapeutic options. J Palliat Med 15(1):106-114. doi:10.1089/jpm.2011.0110 Kamal AH, Maguire JM, Wheeler JL, Currow DC, Abernethy AP (2012) Dyspnea review for the palliative care professional: treatment goals and therapeutic options. J Palliat Med 15(1):106-114. doi:10.​1089/​jpm.​2011.​0110
13.
Zurück zum Zitat dé ric Guirimand F, Sahut M, Laporte L et al (2015) Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer. Cancer Med 4(4):532–539. doi:10.1002/cam4.419 dé ric Guirimand F, Sahut M, Laporte L et al (2015) Sequential occurrence of dyspnea at the end of life in palliative care, according to the underlying cancer. Cancer Med 4(4):532–539. doi:10.​1002/​cam4.​419
14.
Zurück zum Zitat Seow H, Barbera L, Sutradhar R et al (2011) Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 29(9):1151–1158. doi:10.1200/JCO.2010.30.7173 Seow H, Barbera L, Sutradhar R et al (2011) Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 29(9):1151–1158. doi:10.​1200/​JCO.​2010.​30.​7173
15.
Zurück zum Zitat Zeng L, Zhang L, Culleton S et al (2011) Edmonton symptom assessment scale as a prognosticative indicator in patients with advanced cancer. J Palliat Med 14(3):337–342. doi:10.1089/jpm.2010.0438 Zeng L, Zhang L, Culleton S et al (2011) Edmonton symptom assessment scale as a prognosticative indicator in patients with advanced cancer. J Palliat Med 14(3):337–342. doi:10.​1089/​jpm.​2010.​0438
Metadaten
Titel
Impact of dyspnea on advanced cancer patients referred to a palliative radiotherapy clinic
Publikationsdatum
24.03.2017
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2017
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3677-9

Weitere Artikel der Ausgabe 9/2017

Supportive Care in Cancer 9/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.